| Ratchet-like polypeptide translocation mechanism of the AAA+ disaggregase Hsp104 SN Gates, AL Yokom, JB Lin, ME Jackrel, AN Rizo, NM Kendsersky, ... Science 357 (6348), 273-279, 2017 | 264 | 2017 |
| Identification of GPC2 as an oncoprotein and candidate immunotherapeutic target in high-risk neuroblastoma KR Bosse, P Raman, Z Zhu, M Lane, D Martinez, S Heitzeneder, KS Rathi, ... Cancer cell 32 (3), 295-309. e12, 2017 | 184 | 2017 |
| Genomic profiling of childhood tumor patient-derived xenograft models to enable rational clinical trial design JL Rokita, KS Rathi, MF Cardenas, KA Upton, J Jayaseelan, KL Cross, ... Cell reports 29 (6), 1675-1689. e9, 2019 | 165 | 2019 |
| RETRACTED ARTICLE: Cross-HLA targeting of intracellular oncoproteins with peptide-centric CARs M Yarmarkovich, QF Marshall, JM Warrington, R Premaratne, A Farrel, ... Nature 599 (7885), 477-484, 2021 | 100 | 2021 |
| The B7-H3–targeting antibody–drug conjugate m276-SL-PBD is potently effective against pediatric cancer preclinical solid tumor models NM Kendsersky, J Lindsay, EA Kolb, MA Smith, BA Teicher, SW Erickson, ... Clinical Cancer Research 27 (10), 2938-2946, 2021 | 80 | 2021 |
| Epigenomic profiling of neuroblastoma cell lines K Upton, A Modi, K Patel, NM Kendsersky, KL Conkrite, RT Sussman, ... Scientific Data 7 (1), 116, 2020 | 70 | 2020 |
| Synthesis and evaluation of esterified Hsp70 agonists in cellular models of protein aggregation and folding AN Chiang, M Liang, A Dominguez-Meijide, C Masaracchia, ... Bioorganic & medicinal chemistry 27 (1), 79-91, 2019 | 22 | 2019 |
| Targeting of intracellular oncoproteins with peptide-centric CARs M Yarmarkovich, QF Marshall, JM Warrington, R Premaratne, A Farrel, ... Nature 623 (7988), 820-827, 2023 | 19 | 2023 |
| Evaluation of the DLL3-targeting Antibody–Drug Conjugate Rovalpituzumab Tesirine in Preclinical Models of Neuroblastoma K Krytska, CE Casey, J Pogoriler, D Martinez, KS Rathi, A Farrel, ... Cancer research communications 2 (7), 616-623, 2022 | 3 | 2022 |
| ALCAM promotes neuroblastoma proliferation, migration, and immune evasion J Lindsay, M Samanta, N Kendsersky, J Gaither, M Christie, ... Cancer Research 83 (7_Supplement), 6714-6714, 2023 | 1 | 2023 |
| NF-kB is a master regulator of resistance to therapy in high-risk neuroblastoma LD Grossmann, Y Uzun, J Lindsay, CH Chen, C Wingrove, P Gao, ... Cancer Research 82 (12_Supplement), 699-699, 2022 | 1 | 2022 |
| Identification and characterization of chemotherapy resistant high-risk neuroblastoma persister cells LD Grossmann, CH Chen, Y Uzun, A Thadi, AJ Wolpaw, K Louault, ... Cancer Discovery, 2024 | | 2024 |
| Design principles to tailor Hsp104 therapeutics JB Lin, PJ Carman, CW Gambogi, NM Kendsersky, E Chuang, SN Gates, ... bioRxiv, 2024 | | 2024 |
| Discovery and characterization of a p300-selective degrader with potent anti-tumor activity in CBP mutant cancers M Russell, CL Lowenstein, X Zhang, J Roach, J Song, R Nagilla, ... Cancer Research 84 (6_Supplement), 6043-6043, 2024 | | 2024 |
| Discovery of oral SMARCA2 degraders for the treatment of SMARCA4 mutant tumors JC Clemente, L Harikrishnan, S Knight, D Samanta, Z Li, R Rej, R Nagilla, ... Cancer Research 84 (6_Supplement), 6051-6051, 2024 | | 2024 |
| Lineage-dependence of the neuroblastoma surfaceome defines tumor cell state-dependent and independent immunotherapeutic targets NM Kendsersky, M Odrobina, NW Mabe, A Farrel, L Grossmann, M Tsang, ... bioRxiv, 2024.06. 27.600865, 2024 | | 2024 |
| Identification of ADRN-specific, MES-specific, and pan-subtype therapeutic targets in neuroblastoma NM Kendsersky, NW Mabe, A Farrel, LD Grossmann, M Odrobina, ... Cancer Research 82 (12_Supplement), 3889-3889, 2022 | | 2022 |
| Identification and Validation of Subtype-Specific Therapy Targets in Neuroblastoma NM Kendsersky University of Pennsylvania, 2022 | | 2022 |
